

Peter C Adamson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6935214/publications.pdf>

Version: 2024-02-01

185
papers

10,087
citations

38660

50
h-index

39575

94
g-index

189
all docs

189
docs citations

189
times ranked

11306
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 472-480.	5.1	614
2	Understanding and Managing Methotrexate Nephrotoxicity. <i>Oncologist</i> , 2006, 11, 694-703.	1.9	591
3	Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy. <i>New England Journal of Medicine</i> , 2010, 362, 790-799.	13.9	558
4	Declining childhood and adolescent cancer mortality. <i>Cancer</i> , 2014, 120, 2497-2506.	2.0	410
5	Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4536-4545.	1.4	265
6	Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 399-405.	0.8	240
7	Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design. <i>Journal of Clinical Oncology</i> , 2008, 26, 190-195.	0.8	223
8	Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months. <i>Epilepsia</i> , 2013, 54, 141-155.	2.6	219
9	Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 3756-3762.	0.8	211
10	A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2008, 50, 254-258.	0.8	186
11	A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2006, 12, 1750-1759.	3.2	176
12	Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. <i>New England Journal of Medicine</i> , 2020, 382, 2207-2219.	13.9	157
13	A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2007, 13, 1516-1522.	3.2	142
14	Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 452-456.	0.8	132
15	Glucarpidase, Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome. <i>Journal of Clinical Oncology</i> , 2010, 28, 3979-3986.	0.8	130
16	Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma. <i>Clinical Cancer Research</i> , 2014, 20, 4200-4209.	3.2	127
17	Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency. <i>Journal of Clinical Oncology</i> , 2005, 23, 8431-8441.	0.8	113
18	Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4921-4927.	0.8	113

#	ARTICLE	IF	CITATIONS
19	Phase I trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. <i>Blood</i> , 2008, 111, 566-573.	0.6	113
20	Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study (ADVL0015). <i>Journal of Clinical Oncology</i> , 2004, 22, 4804-4809.	0.8	110
21	Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study. <i>Clinical Cancer Research</i> , 2012, 18, 6058-6064.	3.2	110
22	A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2007, 13, 1789-1793.	3.2	106
23	Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2011, 17, 5113-5122.	3.2	104
24	A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report. <i>Clinical Cancer Research</i> , 2012, 18, 6011-6022.	3.2	103
25	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2015, 33, 278-284.	0.8	102
26	Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in Young Infants. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 717-723.	1.1	101
27	Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium. <i>Journal of Clinical Oncology</i> , 2011, 29, 839-844.	0.8	100
28	Proton Magnetic Resonance Spectroscopic Imaging in Children With Recurrent Primary Brain Tumors. <i>Journal of Clinical Oncology</i> , 2000, 18, 1020-1020.	0.8	99
29	Improving the outcome for children with cancer: Development of targeted new agents. <i>Ca-A Cancer Journal for Clinicians</i> , 2015, 65, 212-220.	157.7	99
30	Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6172-6180.	0.8	98
31	A Phase I Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan-Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 5174-5181.	0.8	98
32	Phase I Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children's Oncology Group Report. <i>Clinical Cancer Research</i> , 2011, 17, 589-597.	3.2	92
33	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol (<i>Escherichia coli</i> L-Asparaginase) in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. <i>Journal of Clinical Oncology</i> , 2014, 32, 3874-3882.	0.8	91
34	A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report. <i>Pediatric Blood and Cancer</i> , 2009, 53, 978-983.	0.8	89
35	Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1171-1175.	0.8	89
36	Phase I trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 833-839.	0.8	87

#	ARTICLE	IF	CITATIONS
37	Target and Agent Prioritization for the Children's Oncology Group's National Cancer Institute Pediatric MATCH Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	85
38	Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1450-1456.	1.4	82
39	Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report. <i>Journal of Clinical Oncology</i> , 2006, 24, 3678-3685.	0.8	81
40	New drugs for children and adolescents with cancer: the need for novel development pathways. <i>Lancet Oncology</i> , The, 2013, 14, e117-e124.	5.1	81
41	The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. <i>Critical Care Medicine</i> , 2004, 32, 2318-2322.	0.4	77
42	The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: A multicenter, double-blind, randomized trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 321-328.	0.4	72
43	Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study. <i>Pediatric Blood and Cancer</i> , 2010, 54, 538-545.	0.8	68
44	Population Pharmacokinetics of Dexmedetomidine in Infants After Open Heart Surgery. <i>Anesthesia and Analgesia</i> , 2010, 110, 1383-1392.	1.1	67
45	Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. <i>Cancer</i> , 1995, 76, 521-526.	2.0	63
46	Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1557-1559.	3.0	60
47	Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). <i>Clinical Cancer Research</i> , 2021, 27, 3543-3548.	3.2	59
48	Population Pharmacokinetics of Milrinone in Neonates with Hypoplastic Left Heart Syndrome Undergoing Stage I Reconstruction. <i>Anesthesia and Analgesia</i> , 2006, 102, 1062-1069.	1.1	58
49	Insights into pediatric rhabdomyosarcoma research: Challenges and goals. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27869.	0.8	57
50	Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. <i>Pediatric Blood and Cancer</i> , 2014, 61, 145-150.	0.8	56
51	The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. <i>Leukemia Research</i> , 1994, 18, 805-810.	0.4	55
52	Characteristics and Outcome of Pediatric Patients Enrolled in Phase I Oncology Trials. <i>Oncologist</i> , 2008, 13, 679-689.	1.9	54
53	Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study. <i>Pediatric Blood and Cancer</i> , 2010, 55, 629-638.	0.8	53
54	Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 41-44.	1.1	50

#	ARTICLE	IF	CITATIONS
55	Challenges and opportunities in childhood cancer drug development. <i>Nature Reviews Cancer</i> , 2012, 12, 776-782.	12.8	48
56	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated <i>Erwinia</i> asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26873.	0.8	48
57	Successful Treatment of Intrathecal Methotrexate Overdose by Using Ventriculolumbar Perfusion and Intrathecal Instillation of Carboxypeptidase G2. <i>Mayo Clinic Proceedings</i> , 1996, 71, 161-165.	1.4	47
58	Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study. <i>Neuro-Oncology</i> , 2008, 10, 752-758.	0.6	47
59	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 1537-1543.	0.8	47
60	A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 4882-4887.	3.2	45
61	A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 1111-1115.	3.2	45
62	A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2010, 55, 440-445.	0.8	45
63	Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations. <i>Journal of Clinical Oncology</i> , 2001, 19, 2754-2763.	0.8	44
64	Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. <i>British Journal of Haematology</i> , 2008, 141, 827-839.	1.2	44
65	A pediatric phase I trial and pharmacokinetic study of ispinesib: A Children's Oncology Group phase I consortium study. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1323-1328.	0.8	43
66	Imaging in childhood cancer: A society for pediatric radiology and children's oncology group joint task force report. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1253-1260.	0.8	42
67	Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2010, 16, 750-754.	3.2	41
68	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27747.	0.8	40
69	Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. <i>Pediatric Blood and Cancer</i> , 2004, 43, 780-784.	0.8	39
70	The Pharmacokinetics of Esmolol in Pediatric Subjects with Supraventricular Arrhythmias. <i>Pediatric Cardiology</i> , 2006, 27, 420-427.	0.6	39
71	A phase 2 trial of all-trans-retinoic acid in combination with interferon- α 2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study. <i>Pediatric Blood and Cancer</i> , 2007, 49, 661-665.	0.8	39
72	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. <i>Cancer Genetics</i> , 2016, 209, 182-194.	0.2	38

#	ARTICLE	IF	CITATIONS
73	Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 275-282.	1.1	37
74	Pertussis in a previously immunized child with human immunodeficiency virus infection. <i>Journal of Pediatrics</i> , 1989, 115, 589-592.	0.9	36
75	Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2006, 47, 790-794.	0.8	36
76	Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2013, 60, 237-241.	0.8	34
77	Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence. <i>Progress in Pediatric Cardiology</i> , 2014, 36, 39-49.	0.2	34
78	Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases. <i>Bone</i> , 2018, 109, 276-280.	1.4	34
79	Tissue Collection for Correlative Studies in Childhood Cancer Clinical Trials: Ethical Considerations and Special Imperatives. <i>Journal of Clinical Oncology</i> , 2004, 22, 4846-4850.	0.8	32
80	A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 458-464.	1.1	31
81	A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non-Hodgkin's Lymphoma: A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2007, 13, 5652s-5660s.	3.2	31
82	Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1021-1027.	1.1	31
83	Sporadic Adenocarcinoma of the Colon in Children. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e137-e141.	0.3	30
84	The Bioavailability of Oral Methotrexate in Children with Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2005, 40, 445-449.	0.9	29
85	Drug Utilization in the Pediatric Intensive Care Unit: Monitoring Prescribing Trends and Establishing Prioritization of Pharmacotherapeutic Evaluation of Critically Ill Children. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1305-1312.	1.0	29
86	Survivorship Care Plans and the Commission on Cancer Standards: The Increasing Need for Better Strategies to Improve the Outcome for Survivors of Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 447-450.	1.4	29
87	Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. <i>Journal of Clinical Oncology</i> , 2012, 30, 9500-9500.	0.8	29
88	A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2008, 50, 577-580.	0.8	28
89	A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study. <i>Neuro-Oncology</i> , 2011, 13, 910-915.	0.6	28
90	Drug discovery in paediatric oncology: roadblocks to progress. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 732-739.	12.5	28

#	ARTICLE	IF	CITATIONS
91	Pediatric cancer research: Surviving COVID-19. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28435.	0.8	28
92	ACCELERATE – Five years accelerating cancer drug development for children and adolescents. <i>European Journal of Cancer</i> , 2022, 166, 145-164.	1.3	28
93	A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1990, 26, 343-344.	1.1	27
94	A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. <i>Neuro-Oncology</i> , 2008, 10, 569-576.	0.6	27
95	The Children's Oncology Group Childhood Cancer Research Network (CCRN): Case catchment in the United States. <i>Cancer</i> , 2014, 120, 3007-3015.	2.0	27
96	Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the children's oncology group phase I consortium. <i>Pediatric Blood and Cancer</i> , 2015, 62, 45-51.	0.8	27
97	The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex TM) in a nonhuman primate model. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 439-443.	1.1	26
98	Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: A collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942). <i>Pediatric Blood and Cancer</i> , 2007, 49, 250-255.	0.8	26
99	Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: A Children's Oncology Group trial (P9962). <i>Pediatric Blood and Cancer</i> , 2012, 58, 362-365.	0.8	25
100	Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10011-10011.	0.8	25
101	Amphotericin B in the treatment of Candida cholecystitis. <i>Pediatric Infectious Disease Journal</i> , 1989, 8, 408-410.	1.1	24
102	Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report. <i>Neuro-Oncology</i> , 2022, 24, 655-664.	0.6	24
103	A sensitive and selective liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. <i>Journal of Mass Spectrometry</i> , 2007, 42, 761-770.	0.7	23
104	Population Pharmacokinetic Investigation of Actinomycin-D in Children and Young Adults. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 35-42.	1.0	23
105	Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 77-86.	0.8	23
106	Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26636.	0.8	23
107	Acute pancreatitis after ifosfamide therapy. <i>Cancer</i> , 1994, 74, 1627-1628.	2.0	22
108	A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. <i>Clinical Cancer Research</i> , 2012, 18, 5081-5089.	3.2	22

#	ARTICLE	IF	CITATIONS
109	Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2017, 35, 139-140.	0.8	22
110	New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics. <i>JAMA Oncology</i> , 2018, 4, 1274.	3.4	22
111	Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 829-840.	1.1	22
112	Application of Pharmacogenetics to Optimization of Mercaptopurine Dosing. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1983-1985.	3.0	21
113	Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2011, 56, 226-233.	0.8	21
114	The Children's Oncology Group's 2013 five year blueprint for research. <i>Pediatric Blood and Cancer</i> , 2013, 60, 955-956.	0.8	21
115	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1775-1781.	0.8	21
116	Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2. <i>Blood</i> , 2011, 118, 573-573.	0.6	21
117	The importance of pharmacokinetic limited sampling models for childhood cancer drug development. <i>Clinical Cancer Research</i> , 2003, 9, 5068-77.	3.2	21
118	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. <i>European Journal of Cancer</i> , 2020, 139, 135-148.	1.3	20
119	The impact of chemotherapy shortages on COG and local clinical trials: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 940-944.	0.8	19
120	New Approaches to Drug Development in Pediatric Oncology. <i>Cancer Journal (Sudbury, Mass)</i> , 2005, 11, 324-330.	1.0	18
121	Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3716-3724.	0.8	18
122	Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 737-743.	1.1	16
123	Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1469-1475.	1.1	16
124	Lessons Learned from the Investigational Device Exemption Review of Children's Oncology Group Trial AAML1031. <i>Clinical Cancer Research</i> , 2012, 18, 1547-1554.	3.2	16
125	Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children's Oncology Group (ANBL0621). <i>Pediatric Blood and Cancer</i> , 2014, 61, 990-996.	0.8	16
126	Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. <i>PLoS ONE</i> , 2015, 10, e0143480.	1.1	16

#	ARTICLE	IF	CITATIONS
127	Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors. <i>Cancer</i> , 2009, 115, 1765-1775.	2.0	15
128	Unintended Consequences of Regulatory Initiatives in Childhood Cancer Drug Development. <i>JAMA Pediatrics</i> , 2013, 167, 886.	3.3	15
129	Anticancer effects of fenretinide in human medulloblastoma. <i>Cancer Letters</i> , 2006, 231, 262-269.	3.2	14
130	Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1125-1130.	1.1	14
131	Reasons for participation in optional pharmacokinetic studies in children with cancer: A Children's Oncology Group phase 1 consortium study. <i>Pediatric Blood and Cancer</i> , 2010, 55, 119-122.	0.8	14
132	Quantification of Serum Fentanyl Concentrations from Umbilical Cord Blood During Ex Utero Intrapartum Therapy. <i>Anesthesia and Analgesia</i> , 2012, 114, 1265-1267.	1.1	14
133	A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study. <i>Clinical Cancer Research</i> , 2001, 7, 3034-9.	3.2	14
134	Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts. <i>Biochemical Pharmacology</i> , 1993, 45, 1493-1501.	2.0	12
135	The Children's Oncology Group: Organizational Structure, Membership, and Institutional Characteristics. <i>Journal of Pediatric Oncology Nursing</i> , 2019, 36, 24-34.	1.5	12
136	Tyrosine Kinase Inhibitors in Pediatric Malignancies. <i>Cancer Investigation</i> , 2007, 25, 606-612.	0.6	11
137	It's not easy being small. <i>Pediatric Blood and Cancer</i> , 2010, 54, 341-343.	0.8	11
138	Approaches to Clear Residual Chemotherapeutics From Indwelling Catheters in Children With Cancer. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 741-748.	1.0	10
139	Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia. <i>Pediatric Blood and Cancer</i> , 2007, 49, 687-693.	0.8	9
140	Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 235-240.	1.1	8
141	The plasma pharmacokinetics and cerebral spinal fluid penetration of intravenous topiramate in newborn pigs. <i>Biopharmaceutics and Drug Disposition</i> , 2004, 25, 265-271.	1.1	8
142	When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab. <i>Pediatric Blood and Cancer</i> , 2016, 63, 962-963.	0.8	8
143	A rapid, sensitive and selective liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry method for determination of fenretinide (4-HPR) in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 862, 64-71.	1.2	7
144	A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2369-2373.	1.2	7

#	ARTICLE	IF	CITATIONS
145	Liquid chromatography-electrospray mass spectrometry (LC-MS) method for determination of esmolol concentration in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 796, 293-301.	1.2	6
146	Reply to N.-K.V. Cheung et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 4174-4175.	0.8	6
147	Propofol pharmacokinetics *. <i>Pediatric Critical Care Medicine</i> , 2003, 4, 124-125.	0.2	6
148	A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 155-157.	1.1	5
149	Desulfuration of 6-mercaptopurine. <i>Biochemical Pharmacology</i> , 1993, 46, 1627-1636.	2.0	5
150	Imaging in early phase childhood cancer trials. <i>Pediatric Radiology</i> , 2009, 39, 38-41.	1.1	5
151	THE PHARMACOKINETICS AND PHARMACODYNAMICS OF DEXMEDETOMIDINE IN INFANTS FOLLOWING OPEN HEART SURGERY.. <i>Critical Care Medicine</i> , 2005, 33, A6.	0.4	4
152	CYP2B6*6 or Not CYP2B6*6 That Remains a Question for Precision Medicine and Ketamine!. <i>Anesthesiology</i> , 2016, 125, 1085-1087.	1.3	4
153	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2017, 102, e340-e343.	1.7	4
154	Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear medicine-based estimates of renal function. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27672.	0.8	4
155	Lenalidomide (LMID) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. <i>Blood</i> , 2008, 112, 107-107.	0.6	4
156	A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS7568-TPS7568.	0.8	4
157	The Child with Recurrent Solid Tumor. <i>Pediatric Clinics of North America</i> , 1991, 38, 489-504.	0.9	3
158	Congenital Neuroblastoma Arising in the Deltoid Muscle. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 101-103.	0.3	3
159	Emergent Radiation for Leukemic Optic Nerve Infiltration in a Child Receiving Intrathecal Methotrexate. <i>Practical Radiation Oncology</i> , 2019, 9, 226-230.	1.1	3
160	THE EFFECTS OF CARDIOPULMONARY BYPASS (CPB) AND MODIFIED ULTRAFILTRATION (MUF) ON THE PLASMA PHARMACOKINETICS OF MILRINONE (MLR) IN NEONATES WITH HYPOPLASTIC LEFT HEART SYNDROME (HLHS). <i>Critical Care Medicine</i> , 2002, 30, A155.	0.4	2
161	A tale of three princes and two physicists?the importance of ?Why??. <i>Medical and Pediatric Oncology</i> , 2003, 41, 132-135.	1.0	2
162	RESPONSE: Re: Treatment of Accidental Intrathecal Methotrexate Overdose. <i>Journal of the National Cancer Institute</i> , 2005, 97, 610-611.	3.0	2

#	ARTICLE	IF	CITATIONS
163	Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: A Children's Oncology Group report. <i>Pediatric Blood and Cancer</i> , 2008, 50, 533-536.	0.8	2
164	Preclinical evaluation of pemetrexed in pediatric solid tumors. <i>Pediatric Blood and Cancer</i> , 2011, 57, 1233-1235.	0.8	2
165	Effective Targeting of Leukemic Cells in Children with B-Precursor Acute Lymphoblastic Leukemia Treated with Anti-CD22 (Epratuzumab). A Children's Oncology Group (COG) Study.. <i>Blood</i> , 2006, 108, 2585-2585.	0.6	2
166	A liquid chromatography/tandem mass spectrometry method for determination of obatoclax in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 971, 30-34.	1.2	1
167	Early Phase Pediatric Cancer Trials: Progress Highlights Challenges. <i>Oncologist</i> , 2020, 25, 468-469.	1.9	1
168	Pre-Clinical In Vitro Evaluation of BCL-2 Antisense Compound Genasense™ (G3139; Genta, Inc.) as a Targeted Pro-Apoptotic Agent for Leukemias with t(4;11)(q21;q23) Translocations.. <i>Blood</i> , 2005, 106, 3360-3360.	0.6	1
169	Pan-BCL-2 Family Small Molecule Inhibitor GX015-070 (GeminX, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations.. <i>Blood</i> , 2005, 106, 3368-3368.	0.6	1
170	Current challenges in pediatric drug development. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 883-4.	0.3	1
171	My Patient Portal. <i>Annals of Internal Medicine</i> , 2022, 175, 905.	2.0	1
172	Stress lysis in childhood leukemia. <i>Pediatric Blood and Cancer</i> , 2008, 50, 137-139.	0.8	0
173	Text on Randomized Clinical Trials in Pediatric Oncology. <i>Oncologist</i> , 2008, 13, 93-94.	1.9	0
174	Reply to P.A. Meyers et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e181-e181.	0.8	0
175	Quantification of Serum Fentanyl Concentrations From Umbilical Cord Blood During Ex-Utero Intrapartum Therapy. <i>Survey of Anesthesiology</i> , 2013, 57, 75.	0.1	0
176	It seemed like a good idea at the time. <i>Pediatric Blood and Cancer</i> , 2014, 61, 187-188.	0.8	0
177	Too Few Medicines for Children With Cancer—Reply. <i>JAMA Pediatrics</i> , 2014, 168, 583.	3.3	0
178	The 2016 ASPHO Distinguished Career Award Goes to David G. Poplack, MD. <i>Pediatric Blood and Cancer</i> , 2016, 63, S5-S6.	0.8	0
179	Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. <i>Blood</i> , 2011, 118, 2617-2617.	0.6	0
180	Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7086-7086.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Current approach and recommendations for standardized dosing of anticancer drugs in infants.. Journal of Clinical Oncology, 2016, 34, 10546-10546.	0.8	0
182	The challenge of pediatric oncology: New business models to accelerate innovation.. Journal of Clinical Oncology, 2018, 36, 10528-10528.	0.8	0
183	Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli-Derived Asparaginases. Blood, 2019, 134, 2586-2586.	0.6	0
184	Case study. All for one, or one for all? Commentary. Hastings Center Report, 2007, 37, 13-4.	0.7	0
185	Reply to R. Lakhotia et al. Journal of Clinical Oncology, 2022, , JCO2102912.	0.8	0